Last Updated:
Zydus Lifesciences shares surged 7% to an intraday high of Rs 947.95 on the BSE on Thursday after receiving final approval from USFDA
Zydus Life Shares
Zydus Lifesciences shares surged 7% to an intraday high of Rs 947.95 on the BSE on Thursday after receiving final approval from the US Food and Drug Administration (USFDA) to market Dasatinib tablets in various strengths (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg).
The approved drug is a generic version of Sprycel Tablets, used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in adults, especially those with resistance or intolerance to prior therapies. The tablets will be manufactured at Zydus’ Ahmedabad facility.
According to IQVIA MAT January 2025 data, Dasatinib tablets generated $1.81 billion in annual sales in the U.S. With this approval, Zydus now holds 415 USFDA approvals from 483 ANDA filings since FY 2003-04.
Zydus Lifesciences is a global discovery-driven lifesciences company, and for Q3 FY25, it reported a 29.62% rise in consolidated net profit to Rs 1,023.5 crore, up from Rs 789.6 crore in Q3 FY24. Revenue increased by 16.96% YoY to Rs 5,269.1 crore.
